Researchers report a synthetic molecule can reduce tau and even reverse some neurological damage in mouse models of Alzheimer's disease.
Zolgensma, an FDA approved gene therapy, supplements the production of the SMN protein to improve motor neuron function in children with spinal muscular atrophy after just one dose.
A new study reports on a neurobiological basis for apathy.
Researchers implicate a variant in the UBQLN4 gene as a possible cause of ALS. The variant disrupts cellular processes that drive motor neuron development.
A new study implicates a key cellular mechanism as defective in SMA for the first time, providing a new lead for developing future interventions.
Researchers have identified a compound that can stabilize a protein implicated in ALS and SMN.
Researchers identify Neurexin2 as a new target for potential treatment of spinal muscular atrophy.
A study suggests that spinal muscular atrophy (SMA), a genetic neuromuscular disease in infants and children, results primarily from motor circuit dysfunction, not motor neuron or muscle cell dysfunction, as is commonly thought. In a second study, the researchers identified the molecular pathway in SMA that leads to problems with motor function.
Researchers have identified how specific brain areas change over time in patients with Parkinson's disease.
A new study reveals a link between brain activation, cardiorespiratory fitness and executive function in older adults.
A new drug shows promise for improving outcomes for people with SMA.
GABA plays a vital role in controlling the involuntary tics associated with Tourette Syndrome.
